[1] 朱大龙, 母义民. 中国成人2型糖尿病合并心肾疾病患者降糖药物临床应用专家共识[J]. 中华内分泌代谢杂志, 2020, 36(6): 458-468.
[2] WIVIOTT S D, RAZ I, BONACA M P, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2019, 380(4): 347-357.
[3] HEERSPINK H J, PERKINS B A, FITCHETT D H. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications[J]. Circulation, 2016, 134(10): 752-772.
[4] BARNETT A H, MITHAL A, MANASSIE J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial[J]. Lancet Diabetes Endocrinol, 2014, 2(5): 369-384.
[5] FIORETTO P, STEFANSSON B V, JOHNSSON E, et al. Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment[J]. Diabetologia, 2016, 59(9): 2036-2039.
[6] 袁小利, 王守俊. 达格列净对2型糖尿病肾病患者的临床疗效[J]. 河南医学研究, 2020, 29(11): 1969-1971.
[7] XIN Y, GUO Y, LI Y, et al. Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: A systematic review with an indirect comparison meta-analysis[J]. Saudi J Biol Sci, 2019, 26(2): 421-426.
[8] TAYLOR S I, BLAU J E, ROTHER K I. Possible adverse effects of SGLT2 inhibitors on bone[J]. Lancet Diabetes Endocrinol, 2015, 3(1): 8-10.
[9] NAUCK M A, DEL PRATO S, MEIER J J, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial[J]. Diabetes Care, 2011, 34(9): 2015-2022. |